Endo Buyout Of Auxilium Joins Two Changing Firms
at Investor's Business Daily - Thu Oct 09, 6:00PM CDT
Endo International inked a deal to buy fellow specialty drugmaker Auxilium Pharmaceuticals Thursday after raising its initial bid by nearly 20% to $2.6 billion in cash and stock, or $33.25 a share. Auxilium's shares rose 9% to 32.44, while Endo's...
ENDP: 60.59 (+0.40), VRX: 118.54 (+4.20), QLTI: 3.99 (+0.03), AUXL: 30.35 (-0.06), VVUS: 3.60 (+0.13)
Emergent BioSolutions Revamps Business to Drive Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 08, 4:50PM CDT
Emergent BioSolutions (EBS) has decided to restructure its operations.
MDVN: 92.54 (+2.91), EBS: 21.24 (+0.35), VVUS: 3.60 (+0.13), PDLI: 8.13 (+0.50)
3 Biotech Stocks Near 52-Week Lows Worth Buying
Motley Fool Staff - Motley Fool - Wed Oct 08, 7:35AM CDT
Source: Pixabay. While the broad-based SPDR S&P Biotech ETF has galloped higher by 20% year-to-date, a number of biotech stocks are wallowing near their 52-week lows. Could there be bargains to be had among this sea of red? With that in...
OREX: 4.19 (+0.21), VVUS: 3.60 (+0.13), NPSP: 26.42 (+1.49), ARNA: 4.04 (+0.21), EXEL: 1.62 (+0.07)
Halozyme's PEGPH20 Receives FDA Orphan Drug Designation - Analyst Blog
Kanchan Khanna - Zacks Investment Research - Tue Oct 07, 4:40PM CDT
Halozyme Therapeutics, Inc. (HALO) has gained orphan drug status for PEGPH20 for the treatment of pancreatic cancer.
HALO: 9.20 (+0.21), CBM: 17.93 (+1.02), VVUS: 3.60 (+0.13), LGND: 48.86 (+2.58)
Regeneron's Eye Drug Eylea Wins Another FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 07, 3:30PM CDT
Regeneron's (REGN) Eylea has received FDA approval for treating RVO patients.
VVUS: 3.60 (+0.13), REGN: 340.71 (+5.96), PDLI: 8.13 (+0.50)
Newly Published Data Highlight the Effects of Weight Loss With Qsymia in Type 2 Diabetes
Marketwire - Mon Oct 06, 6:01AM CDT
VIVUS, Inc. (NASDAQ: VVUS) today announced the publication of a paper examining study results that demonstrate the positive impact of weight loss with Qsymia® (phentermine and topiramate extended-release) capsules CIV (PHEN/TPM ER) plus lifestyle modification on glycemic control in subjects with type 2 diabetes.
VVUS: 3.60 (+0.13)
Is VIVUS Inc. a Short Sell?
George Budwell, The Motley Fool - Motley Fool - Sat Oct 04, 12:45PM CDT
Short selling is a high risk, high reward investing strategy that requires a rock-solid investing thesis to pull off successfully. Even then, short sellers often guess wrong and pay dearly in the form of a so-called "short squeeze." Healthcare and...
OREX: 4.19 (+0.21), AUXL: 30.35 (-0.06), VVUS: 3.60 (+0.13), ARNA: 4.04 (+0.21), NVS: 85.02 (-1.20)
VIVUS and Auxilium Announce Stendra Label Expansion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 5:25PM CDT
VIVUS, Inc. (VVUS) and Auxilium Pharmaceuticals, Inc. (AUXL) announced that the FDA has approved Stendra's supplemental new drug application.
GILD: 96.88 (+0.72), AUXL: 30.35 (-0.06), VVUS: 3.60 (+0.13), AMGN: 130.45 (-0.45)
Nasdaq stocks posting largest volume increases
AP - Fri Sep 19, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
CNQR: 127.77 (+0.58), ELOS: 8.64 (+0.20), EMKR: 5.63 (+0.05), EVBS: 6.14 (+0.04), MSON: 9.29 (+0.30), VVUS: 3.60 (+0.13), HSON: 3.40 (+0.05), RPRX: 10.51 (+0.43), PFBX: 13.25 (+0.01), MCHX: 3.89 (unch)
Most active Nasdaq-traded stocks
AP - Fri Sep 19, 5:02PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
CNQR: 127.77 (+0.58), MU: 28.30 (+0.76), GILD: 96.88 (+0.72), FB: 72.63 (-0.58), VVUS: 3.60 (+0.13), MSFT: 42.74 (-0.48), INTC: 30.85 (-0.42), ZNGA: 2.29 (+0.01), AAPL: 96.26 (-1.28), CSCO: 22.82 (-0.14)
Oracle and Concur are big market movers
AP - Fri Sep 19, 3:40PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
DRC: 80.81 (+1.20), CLR: 55.92 (+2.07), CAG: 33.29 (-0.33), VVUS: 3.60 (+0.13), SNE: 16.89 (-0.15), JBLU: 11.22 (+0.92), COL: 74.23 (+0.13), ORCL: 37.56 (-0.74), RAD: 4.61 (-0.06), CNQR: 127.77 (+0.58), TIBX: 22.82 (-0.14), PIR: 12.30 (-0.02), RHT: 54.93 (+0.06), MCHX: 3.89 (unch)
3 Biotechs Investors Should Watch
Brian Orelli, The Motley Fool - Motley Fool - Fri Sep 19, 12:49PM CDT
In the heathcare version of "Where the Money Is", guest Brian Orelli joins regulars Michael Douglass and David Williamson to discuss the state of the healthcare sector. In M&A news, Endo International has made an unsolicited bid to acquire ...
ZFGN: 17.92 (+0.26), OREX: 4.19 (+0.21), BIIB: 302.74 (-2.95), ACT: 222.07 (+4.83), ISIS: 40.56 (+1.59), AZN: 67.56 (-0.85), AUXL: 30.35 (-0.06), VVUS: 3.60 (+0.13), AMGN: 130.45 (-0.45), LLY: 61.90 (-0.97), ARNA: 4.04 (+0.21)
VIVUS Inc. (VVUS) Rises: Stock Adds 12.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 8:32AM CDT
VIVUS Inc. (VVUS) was a big mover last session, as the company saw its shares rise more than 12% on the day.
CBPO: 50.80 (+0.57), CBM: 17.93 (+1.02), GILD: 96.88 (+0.72), VVUS: 3.60 (+0.13)
Critical Alerts For FireEye, VIVUS, Ebix, 58.com and Walter Energy Released By InvestorsObserver
PR Newswire - Fri Sep 19, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FEYE, VVUS, EBIX, WUBA and WLT.
WUBA: 36.62 (+0.69), FEYE: 28.96 (+2.16), VVUS: 3.60 (+0.13), WLT: 2.04 (+0.26), EBIX: 13.82 (+0.35)
Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent
PR Newswire - Fri Sep 19, 7:15AM CDT
BioTech News Coverage: Progress made as biotech companies release latest developments, patents and results of studies and trials. Companies in focus are: GenSpera Inc. (OTC: GNSZ), Eli Lilly and Company (NYSE: LLY), Gilead Sciences Inc. (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA)
GILD: 96.88 (+0.72), AUXL: 30.35 (-0.06), VVUS: 3.60 (+0.13), LLY: 61.90 (-0.97), ARNA: 4.04 (+0.21), DOW: 44.76 (+0.67), CELG: 86.38 (-0.17), CELGZ: 3.61 (+0.09)
Market Maker Surveillance Report. MSON, VVUS, CNQR, PIP, CREG, CRRS, Winning Stocks With Lowest Price Friction For Thursday, September 18th 2014
M2 - Fri Sep 19, 4:02AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4944 companies with "abnormal" market making, 2520 companies with positive Friction Factors and 2350 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Thursday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Misonix Inc (NASDAQ:MSON), Vivus Inc (NASDAQ:VVUS), Concur Technologies Inc (NASDAQ:CNQR), PharmAthene Inc (NYSE
CREG: 1.22 (+0.03), CNQR: 127.77 (+0.58), MSON: 9.29 (+0.30), PIP: 1.73 (+0.02), VVUS: 3.60 (+0.13), CRRS: 1.33 (-0.01)
Vivus Set to Possibly Pullback After Yesterday's Rally of 12.37%
Comtex SmarTrend(R) - Thu Sep 18, 4:16PM CDT
Vivus (NASDAQ:VVUS) traded in a range yesterday that spanned from a low of $4.21 to a high of $4.82. Yesterday, the shares gained 12.4%, which took the trading range above the 3-day high of $4.07 on volume of 34.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VVUS: 3.60 (+0.13)
Why VIVUS, Inc. Is Today's Best Biotech Stock
Sean Williams, The Motley Fool - Motley Fool - Thu Sep 18, 12:26PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of VIVUS , a biopharmaceutical company...
OREX: 4.19 (+0.21), AUXL: 30.35 (-0.06), VVUS: 3.60 (+0.13), ARNA: 4.04 (+0.21)
FDA OKs faster-acting label for ED drug Stendra
By The Associated Press - AP - Thu Sep 18, 11:21AM CDT
Federal regulators have approved a new label for Vivus' impotence drug, stating that it becomes effective in half the time that the previous label had stated.
AUXL: 30.35 (-0.06), PFE: 27.70 (-0.49), VVUS: 3.60 (+0.13)